本文選題：多發(fā)性骨髓瘤 + 硼替佐米　； 參考：《新疆醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:研究以硼替佐米聯(lián)合地塞米松及沙利度胺化療方案治療多發(fā)性骨髓瘤(MM)的療效和不良反應(yīng)。方法:29例患者均采用硼替佐米聯(lián)合地塞米松及沙利度胺化療方案:硼替佐米均為1.3mg/m2,在治療第1、4、8、11天靜脈推注給予;地塞米松20-40mg/d,靜脈滴注,第1-2,8-9,15-16天(或者4.5-13.5mg/m2,第1-4天、第9-12天、第17-20天);沙利度胺50-200mg口服,每天一次。21天為1個(gè)療程。結(jié)果:29例多發(fā)性骨髓瘤患者中,初治MM患者19例,復(fù)發(fā)或難治性MM患者10例,總有效率為89.65%(26/29),CR率為27.58%(8/29)。初治組患者中,總有效率為100%(19/19),其中CR8例,VGPR6例,PR5例。在10例復(fù)發(fā)難治患者中,總反應(yīng)率為70%(7/10),其中VGPR3例,PR4例,SD2例,PD1例。主要不良反應(yīng)包括消化系統(tǒng)不良反應(yīng)、血液系統(tǒng)不良反應(yīng)、周圍神經(jīng)病變、感染(以細(xì)菌為主,2例患者出現(xiàn)帶狀皰疹病毒感染)等,經(jīng)相應(yīng)的藥物對(duì)癥治療后可改善,但少數(shù)周圍神經(jīng)病變患者出現(xiàn)較重的藥物不良反應(yīng)。結(jié)論:硼替佐米化療方案治療初治和復(fù)發(fā)、難治性多發(fā)性骨髓瘤患者起效較快,治療有效率高,不良反應(yīng)發(fā)生率較低。
[Abstract]:Aim: to study the efficacy and side effects of bortezomide combined with dexamethasone and thalidomide in the treatment of multiple myeloma. Methods Twenty nine patients were treated with bortezomil combined with dexamethasone and thalidomide chemotherapy regimen: bortezomib was 1.3 mg / m ~ (2), given intravenously on the 1st day of treatment at 811 d, dexamethasone 20-40 mg / d, intravenously, 1-28-915-16 days (or 4.5-13.5mg / m2, 1-4, 9-12 days), Thalidomide 50-200mg was given orally, once a day. 21 days as a course of treatment. Results among 29 cases of multiple myeloma, 19 cases were newly treated MM and 10 cases were relapsed or refractory MM. The total effective rate was 89.65% 26% 29% and the CR rate was 27.58%. In the first treatment group, the total effective rate was 100% 19 / 19, of which 6 cases were CR8 cases with VGPRs and 5 cases with PR1. In 10 patients with refractory recurrence, the total response rate was 70% 10%, of which 3 cases were VGPR3 cases with PR4 cases with SD2 cases with PD. The main adverse reactions include digestive system adverse reactions, blood system adverse reactions, peripheral neuropathy, infection (mainly bacterial infection of herpes zoster virus) and so on. However, a few patients with peripheral neuropathy had severe adverse drug reactions. Conclusion: bortezomil regimen is effective in the treatment of primary and recurrent multiple myeloma patients, and the effective rate is high, and the incidence of adverse reactions is low.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R733.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 王苓;唐f，

本文編號(hào)：1996845